Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-10-22
Target enrollment:
Participant gender:
Summary
When multi-kinase inhibitors based therapies (sorafenib and regorafenib) are limited in
late-stage liver cancer patients, there is no alternative options. PD-1 blockade has became a
promising immunotherapeutic strategy in many cancers. While it showed limited efficacy in
liver cancer. Polyinosinic-polycytidylic acid (PolyIC) has been widely studied as a new
anti-tumor drug and recent study showed that polyIC and PD-L1 mAb has a quite synergetic
effect on the hepatocellular carcinoma (HCC). This study is aimed to evaluate the safety and
efficacy of the combination of PolyIC and PD-1 mAb in unresectable late-stage HCC patients.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University